Genomics of Signaling Crosstalk of Estrogen Receptor α in Breast Cancer Cells
Peter Dudek, Didier Picard · 2008
Read Genomics of Signaling Crosstalk of Estrogen Receptor α in Breast Cancer Cells by Peter Dudek, Didier Picard (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0001859.txt.
Introduction
Peter Dudek and Didier Picard mapped estrogen receptor signaling crosstalk in breast cancer cells in a 2008 PLOS ONE research article. Estrogen receptor alpha is a transcription factor switched on by ligands. A wide variety of other extracellular signals can activate it in the absence of estrogen. The impact of these alternate modes of activation on gene patterns had not been charted.
Their genome study maps the signaling crosstalk of estrogen receptor alpha in breast cancer cells: which gene programs each route yields. The full text gives the gene patterns and the shared ground. Hormone therapy resistance in breast cancer often uses these alternate routes, so charting them helps design later treatments.
Catalog record
| CREATOR | Peter Dudek, Didier Picard |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001859
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Genomics of Signaling Crosstalk of Estrogen Receptor α in Breast Cancer Cells Authors: Peter Dudek, Didier Picard Published: 2008, PLOS ONE DOI: 10.1371/journal.pone.0001859 ABSTRACT The estrogen receptor α (ERα) is a ligand-regulated transcription factor. However, a wide variety of other extracellular signals can activate ERα in the absence of estrogen. The impact of these alternate modes of activation on gene expression profiles has not been characterized. We show that estrogen, growth factors and cAMP elicit surprisingly distinct ERα-dependent transcriptional responses in human MCF7 breast cancer cells. In response to growth factors and cAMP, ERα primarily activates and represses genes, respectively. The combined treatments with the anti-estrogen tamoxifen and cAMP or growth factors regulate yet other sets of genes. In many cases, tamoxifen is perverted to an agonist, potentially mimicking what is happening in certain tamoxifen-resistant breast tumors and emphasizing the importance of the cellular signaling environment. Using a computational analysis, we predicted that a Hox protein might be involved in mediating such combinatorial effects, and then confirmed it experimentally. Although both tamoxifen and cAMP block the proliferation of MCF7 cells, their combined application stimulates it, and this can be blocked with a dominant-negative Hox mutant. The activating signal dictates both target gene selection and regulation by ERα, and this has consequences on global gene expression patterns that may be relevant to understanding the progression of ERα-dependent carcinomas. INTRODUCTION In reproductive tissues, estrogens and peptide growth factors (GFs) are mitogenic and play important roles in the normal and aberrant development. The first indication that these signaling pathways communicate with each other was the observation that serum, insulin and IGF-I can stimulate ERα activity [1] . Indeed, ERα has been shown to be activated as a transcription factor by many signaling pathways even in the absence of its cognate ligand estrogen ( [2] ; and http://www.picard.ch/downloads/downloads.htm ). The biological cooperation between the EGF and IGF-I receptor pathways and ERα is the best studied to date. Antibodies against EGF inhibit estrogen-induced proliferation of uterine tissue [3] and the ER antagonist ICI164,384 reduces the response to EGF [4] . This relationship was confirmed genetically, since studies with ERα knockout mice showed a requirement for ERα for EGF-induced uterine growth [5] , [6] . Moreover, the estrogen-dependent proliferation of the uterine stroma is defective in EGF receptor knockout mice [7] . In cultured cells, IGF-I is able to stimulate the transcriptional activity of ERα in the absence of hormone [8] , [9] . The estrogen-independent activation of ERα by EGF requires the direct phosphorylation of ERα by MAPK [10] and this allows the recruitment of both positive and negative coregulators [11] . Elevated levels of cAMP also activate ERα in a ligand-independent fashion, but little is known about the mechanism of this response [12] , [13] . Dopamine D1 receptor agonists like dopamine, which lead to increased levels of cAMP and activation of protein kinase A (PKA), have been shown to activate ERα in the absence of hormone [14] . PKA has been shown to modulate ERα function by phosphorylating the ERα residues S167, S236 and S305 [15] – [18] . However, there is no evidence that the PKA-elicited hormone-independent activation of ERα is a consequence of direct phosphorylation [19] , and we have recently found that this activation is mediated by the phosphorylation-induced interaction with a transcriptional coactivator (P.D. et al., unpublished results). Although the role of estrogen signaling for breast cancer has been extensively studied, it is not clear to what extent ligand-independent activation of ERα contributes to breast cancer progression to estrogen-independent or endocrine therapy-resistant forms. Overexpression or activation of the EGF receptor ErbB2 (also known as HER2 and Neu) or activation of MEKK1 has been shown to lead to resistance to the anti-estrogen tamoxifen in cell culture ( [20] – [22] , see also ref. [23] ). Inhibition of ErbB2 or the p42/44 MAP kinases Erk1/2 restored the inhibitory effects of tamoxifen, underlining the importance of the MAPK pathway in regulating cellular growth in these systems [24] . Indeed, in clinical samples, Erk1/2 have been observed to be hyperactive and overexpressed in malignant breast tumors [25] and their activity correlates with a poor response to endocrine therapy and decreased survival of patients [26] . Furthermore, breast tumor-derived cells that exhibit elevated MAPK expression are hypersensitive to estradiol [27] . Interestingly, the ER coactivator SRC3 is amplified in breast and ovarian cancers [28] , and is itself a target of the p42/44 MAPK pathway [29] . In a retrospective clinical study on tamoxifen treatment, co-overexpression of SRC3 with ErbB2 was correlated with the poorest outcomes in patients treated with tamoxifen [30] . The cAMP/PKA pathway may also contribute to endocrine resistance. Indeed, higher levels of cAMP-binding proteins were isolated from breast tumor samples that were resistant to endocrine therapy, compared with those that were not, suggesting the presence of a very active cAMP/PKA pathway [31] . A gene profiling study showed that the expression of one of the regulatory subunits of PKA, RIα, is significantly reduced in primary breast tumor samples and correlates with tamoxifen insensitivity [32] . This may be due to a hyperactive PKA phosphorylating ERα on S305 and locking it into a different conformation in the presence of tamoxifen [17] , [18] . A considerable number of studies have been published that used DNA microarray technology to characterize the gene expression responses of breast cancer cells to estrogens and anti-estrogens (for example, refs. [33] – [38] ). Except for one study that compared the GF responses of the uterus of ERα knock-out and wild-type mice [39] , the impact of ligand-independent activation of ERα has not been investigated at the genomic level. We used microarray technology to determine whether different modes of activation of ERα lead to similar or different genomic responses and how those are affected by tamoxifen in human MCF7 breast cancer cells. We then performed a computational analysis on a set of target genes to predict the involvement of additional transcription factors and experimentally confirmed that some are responsible for the proliferative stimulus of the combined treatment of MCF7 cells with cAMP and tamoxifen. RESULTS Recent studies concluded that the ERα-positive human breast carcinoma cell line MCF7 is an excellent model system for gene expression studies since the gene expression profiles are nearly identical to ERα-positive breast tumor xenografts and primary tumors [37] . Here we analyzed signaling crosstalk-specific profiles with MCF7 cells using a human cDNA array. To ensure that the expression profiles would be due to primary transcriptional responses, cells were induced for only 4 hours and in the presence of the translation inhibitor cycloheximide. Details on the experimental design and methodology are given in Supporting Information Text S1 , and the treatments are listed and illustrated in Supporting Information Table S1 and Figure S1A , respectively. 220 unique transcripts of the 9,480 represented on the cDNA arrays responded to at least one of the three treatments by at least 2-fold ( Figure 1A and Supporting Information Table S2 ). The genes regulated in the sample treated with 17β-estradiol (E2) accounted for 90 (40.9%) of all regulated genes, including many genes known to be regulated by E2 such as PGR (progesterone receptor gene), BCL2